A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01017952 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1635

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: FF/GW642444 Inhalation Powder
DRUG: GW642444 Inhalation Powder

Sponsor

GlaxoSmithKline